GRCE

Grace Therapeutics, Inc. (GRCE) - Q2 2024 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended September 30, 2024. Grace Therapeutics, Inc. (formerly Acasti Pharma Inc.) is a clinical-stage biopharmaceutical company focused on developing novel drug delivery technologies for rare and orphan diseases. The company recently completed a corporate domestication from Canada to Delaware and changed its trading symbol to "GRCE" on October 28, 2024. The company has no product revenue and is heavily dependent on the development of its lead candidate, GTx-104.

Key Financial Metrics

Material Changes vs. Prior Period

• Operating Expenses: Research and development (R&D) expenses increased significantly to $3.0 million for the quarter (from $0.5 million in the prior year quarter) and $5.7 million for the six-month period (from $1.6 million). This increase is primarily due to the advancement of the pivotal Phase 3 STRIVE-ON safety trial for GTx-104.
• Net Loss: The net loss for the six months ended September 30, 2024, decreased by $1.3 million compared to the prior year period. This improvement was driven by a $3.6 million favorable change in the fair value of derivative warrant liabilities and a reduction in restructuring costs (which were $1.5 million in the prior year period but $0 in the current period).
• Liquidity: Cash and cash equivalents decreased by $7.9 million from the beginning of the fiscal year ($23.0 million) to $15.2 million, reflecting ongoing operational burn.
• Corporate Structure: The company completed a continuance and domestication to Delaware in October 2024, changing its name from Acasti Pharma Inc. to Grace Therapeutics, Inc.

Guidance, Outlook, and Risks

• Clinical Milestones: The company announced the completion of patient enrollment in the Phase 3 STRIVE-ON safety trial for GTx-104 on September 25, 2024. A data readout is anticipated in the first calendar quarter of 2025, with a planned New Drug Application (NDA) submission to the FDA in the first half of 2025.
• Liquidity Outlook: Management believes existing cash resources are sufficient to fund operations into the second calendar quarter of 2026. However, the company will require additional capital to fund daily operations beyond that time and to complete development.
• Pipeline Strategy: Development of secondary candidates GTx-102 (Ataxia Telangiectasia) and GTx-101 (Postherpetic Neuralgia) has been deprioritized to focus resources on GTx-104. Future development of these candidates is contingent on securing additional funding or strategic partnerships.
• Risks: Key risks include the uncertainty of clinical trial outcomes, the need for additional financing which may be dilutive, and the company's heavy dependence on the success of GTx-104. The filing notes that if the company cannot raise capital, it may not be able to realize its assets or discharge liabilities.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $15.2 million cash balance against the projected burn rate to confirm the "Q2 2026" liquidity estimate.
• Phase 3 Trial Status: Monitor the upcoming Q1 2025 data readout for the STRIVE-ON trial, as this is the primary catalyst for the company's valuation.
• Financing Needs: Assess the likelihood and terms of future capital raises required post-2026, given the lack of revenue and high R&D costs.
• Derivative Liabilities: Review the volatility of the $2.6 million derivative warrant liability, which significantly impacts reported net loss but is a non-cash item.
• Contractual Commitments: Note the $3.9 million in commitments to Contract Research Organizations (CROs) and $0.4 million to Contract Manufacturing Organizations (CMOs) for the next 12 months.